Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Standard blood pressure control metrics may not account for fluctuations in blood pressure over time.
OBJECTIVES: This study sought to estimate the independent association between time in systolic blood pressure target range and major adverse cardiovascular events among adults with hypertension.
METHODS: This study was a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a randomized clinical trial that compared intensive (<120 mm Hg) and standard (<140 mm Hg) systolic blood pressure treatment interventions in adults with hypertension and high cardiovascular risk. Target range was defined as 110 to 130 mm Hg and 120 to 140 mm Hg for the intensive and standard arms, respectively. Time in target range was estimated over the first 3 months of follow-up using linear interpolation. The association between time in target range with major adverse cardiovascular events was estimated using adjusted Cox proportional hazards regression models.
RESULTS: Participants with greater time in target range were younger, had lower 10-year cardiovascular risk and lower baseline systolic blood pressure, and were more likely women and statin users. Each 1-SD increase in time in target range was significantly associated with a decreased risk of first major adverse cardiovascular event in fully adjusted models. Time in target range remained significantly associated with major adverse cardiovascular events despite adjustment for mean systolic blood pressure or systolic blood pressure variability. Among participants with mean systolic blood pressure at or below target, time in target range remained associated with major adverse cardiovascular events.
CONCLUSIONS: Time in systolic blood pressure target range independently predicts major adverse cardiovascular event risk.
Errataetall: |
CommentIn: J Am Coll Cardiol. 2021 Mar 16;77(10):1300-1301. - PMID 33706871 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
---|---|
Enthalten in: |
Journal of the American College of Cardiology - 77(2021), 10 vom: 16. März, Seite 1290-1299 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Fatani, Nayyra [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antihypertensive Agents |
---|
Anmerkungen: |
Date Completed 30.09.2021 Date Revised 17.03.2022 published: Print CommentIn: J Am Coll Cardiol. 2021 Mar 16;77(10):1300-1301. - PMID 33706871 Citation Status MEDLINE |
---|
doi: |
10.1016/j.jacc.2021.01.014 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM322637678 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM322637678 | ||
003 | DE-627 | ||
005 | 20231225182450.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jacc.2021.01.014 |2 doi | |
028 | 5 | 2 | |a pubmed24n1075.xml |
035 | |a (DE-627)NLM322637678 | ||
035 | |a (NLM)33706870 | ||
035 | |a (PII)S0735-1097(21)00080-2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Fatani, Nayyra |e verfasserin |4 aut | |
245 | 1 | 0 | |a Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.09.2021 | ||
500 | |a Date Revised 17.03.2022 | ||
500 | |a published: Print | ||
500 | |a CommentIn: J Am Coll Cardiol. 2021 Mar 16;77(10):1300-1301. - PMID 33706871 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. | ||
520 | |a BACKGROUND: Standard blood pressure control metrics may not account for fluctuations in blood pressure over time | ||
520 | |a OBJECTIVES: This study sought to estimate the independent association between time in systolic blood pressure target range and major adverse cardiovascular events among adults with hypertension | ||
520 | |a METHODS: This study was a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a randomized clinical trial that compared intensive (<120 mm Hg) and standard (<140 mm Hg) systolic blood pressure treatment interventions in adults with hypertension and high cardiovascular risk. Target range was defined as 110 to 130 mm Hg and 120 to 140 mm Hg for the intensive and standard arms, respectively. Time in target range was estimated over the first 3 months of follow-up using linear interpolation. The association between time in target range with major adverse cardiovascular events was estimated using adjusted Cox proportional hazards regression models | ||
520 | |a RESULTS: Participants with greater time in target range were younger, had lower 10-year cardiovascular risk and lower baseline systolic blood pressure, and were more likely women and statin users. Each 1-SD increase in time in target range was significantly associated with a decreased risk of first major adverse cardiovascular event in fully adjusted models. Time in target range remained significantly associated with major adverse cardiovascular events despite adjustment for mean systolic blood pressure or systolic blood pressure variability. Among participants with mean systolic blood pressure at or below target, time in target range remained associated with major adverse cardiovascular events | ||
520 | |a CONCLUSIONS: Time in systolic blood pressure target range independently predicts major adverse cardiovascular event risk | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a hypertension | |
650 | 4 | |a quality of care | |
650 | 4 | |a time in target range | |
650 | 7 | |a Antihypertensive Agents |2 NLM | |
700 | 1 | |a Dixon, Dave L |e verfasserin |4 aut | |
700 | 1 | |a Van Tassell, Benjamin W |e verfasserin |4 aut | |
700 | 1 | |a Fanikos, John |e verfasserin |4 aut | |
700 | 1 | |a Buckley, Leo F |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of the American College of Cardiology |d 1987 |g 77(2021), 10 vom: 16. März, Seite 1290-1299 |w (DE-627)NLM012608602 |x 1558-3597 |7 nnns |
773 | 1 | 8 | |g volume:77 |g year:2021 |g number:10 |g day:16 |g month:03 |g pages:1290-1299 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacc.2021.01.014 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 77 |j 2021 |e 10 |b 16 |c 03 |h 1290-1299 |